Kirkland & Ellis advised Suzhou Basecare Medical Corporation Limited (HKSE: 2170), an innovative platform of genetic testing solutions for assisted reproduction in China, in its $233 million global offering of H-shares and listing on the Hong Kong Exchanges and Clearing Limited. The listing took place on February 8, 2021.
Read more in Suzhou Basecare Medical’s listing document
The Kirkland team was led by capital markets partner Mengyu Lu.
